NASDAQ:IART • US4579852082
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INTEGRA LIFESCIENCES HOLDING (IART).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-11 | Citigroup | Maintains | Sell -> Sell |
| 2026-02-27 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-03 | Truist Securities | Reiterate | Hold -> Hold |
| 2025-10-31 | JP Morgan | Maintains | Underweight -> Underweight |
| 2025-10-31 | Citigroup | Maintains | Sell -> Sell |
| 2025-10-15 | Truist Securities | Maintains | Hold -> Hold |
| 2025-10-07 | Citigroup | Maintains | Sell -> Sell |
| 2025-05-09 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-05-06 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-06 | JP Morgan | Maintains | Underweight -> Underweight |
| 2025-04-11 | Truist Securities | Maintains | Hold -> Hold |
| 2025-03-31 | Argus Research | Upgrade | Hold -> Buy |
| 2025-02-26 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-05 | Citigroup | Maintains | Sell -> Sell |
| 2024-10-14 | Truist Securities | Maintains | Hold -> Hold |
| 2024-10-07 | BTIG | Upgrade | Sell -> Neutral |
| 2024-10-07 | B of A Securities | Maintains | Underperform -> Underperform |
| 2024-10-01 | Citigroup | Maintains | Sell -> Sell |
| 2024-08-28 | BTIG | Maintains | Sell -> Sell |
| 2024-08-22 | Citigroup | Maintains | Sell -> Sell |
| 2024-07-30 | BTIG | Downgrade | Neutral -> Sell |
| 2024-07-30 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-07-30 | Truist Securities | Maintains | Hold -> Hold |
| 2024-07-30 | Citigroup | Downgrade | Neutral -> Sell |
| 2024-07-16 | Truist Securities | Maintains | Hold -> Hold |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.542B -1.04% | 1.611B 4.47% | 1.635B 1.53% | 1.708B 4.45% | 1.766B 3.40% | 1.82B 3.06% | |
| EBITDA YoY % growth | 395.289M -3.92% | 323.524M -18.16% | 324.78M 0.39% | 343.72M 5.83% | 372.76M 8.45% | 392.63M 5.33% | |
| EBIT YoY % growth | 271.777M -7.27% | 182.631M -32.80% | 172.948M -5.30% | 292.58M 69.17% | 310.25M 6.04% | 330.81M 6.63% | |
| Operating Margin | 17.63% | 11.34% | 10.58% | 17.13% | 17.57% | 18.18% | |
| EPS YoY % growth | 3.10 -7.46% | 2.56 -17.42% | 2.23 -12.89% | 2.39 7.01% | 2.60 8.96% | 2.79 7.36% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.41 0.63% | 0.54 19.09% | 0.59 9.72% | 0.86 3.12% | 0.53 29.17% | 0.65 21.82% | 0.68 14.05% | 0.81 -5.85% |
| Revenue Q2Q % growth | 389.51M 1.79% | 433.91M 4.40% | 425.53M 5.84% | 458.4M 5.40% | 402.73M 3.39% | 451.11M 3.96% | 442.71M 4.04% | 475.69M 3.77% |
| EBITDA Q2Q % growth | 67.395M 5.52% | 78.048M -27.97% | 84.846M -44.80% | 110.22M -50.87% | 75.888M 12.60% | 92.412M 18.40% | 97.104M 14.45% | 112.3M 1.89% |
| EBIT Q2Q % growth | 56.313M 111.07% | 67.863M 102.73% | 71.951M 78.58% | 97.047M 33.85% | 60.282M 7.05% | 74.562M 9.87% | 79.56M 10.58% | 99.297M 2.32% |
All data in USD
17 analysts have analysed IART and the average price target is 16.66 USD. This implies a price increase of 81.09% is expected in the next year compared to the current price of 9.2.
INTEGRA LIFESCIENCES HOLDING (IART) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of INTEGRA LIFESCIENCES HOLDING (IART) is 0.41 USD and the consensus revenue estimate is 389.51M USD.
The consensus rating for INTEGRA LIFESCIENCES HOLDING (IART) is 54.1176 / 100 . This indicates that analysts generally have a neutral outlook on the stock.